News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
US Panel Rejects Genentech, Inc.'s Avastin for Treating Breast Cancer
December 5, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
GAITHERSBURG, Md., Dec 5 (Reuters) - Cancer drug Avastin should not be approved to treat women with breast cancer, a U.S. advisory panel recommended on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Postmarket research
FDA
Approvals
Genentech, Inc.
MORE ON THIS TOPIC
Policy
Disc Shares Slip Amid Report FDA’s Prasad is Skeptical of Bitopertin’s Efficacy
December 22, 2025
·
2 min read
·
Nick Paul Taylor
Lung cancer
AstraZeneca’s ATR Inhibitor Fails to Improve Survival in Phase III Lung Cancer Trial
December 22, 2025
·
1 min read
·
Annalee Armstrong
China
AstraZeneca Finds Another Jewel in China With up to $2B For KRAS Inhibitor
December 22, 2025
·
1 min read
·
Annalee Armstrong
Approvals
Cytokinetics Wins FDA Approval, Clearing Way to Challenge BMS in Heart Disease Market
December 22, 2025
·
2 min read
·
Nick Paul Taylor
